These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 39094802)

  • 1. Abortion Stigma as a Barrier to Mifepristone Use among Obstetrician-Gynecologists in Alabama for Early Pregnancy Loss.
    Mokashi M; Boulineaux C; Janiak E; Boozer M; Neill S
    South Med J; 2024 Aug; 117(8):504-509. PubMed ID: 39094802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of early pregnancy loss among obstetrician-gynecologists in Massachusetts and barriers to mifepristone use.
    Neill S; Hoe E; Fortin J; Goldberg AB; Janiak E
    Contraception; 2023 Oct; 126():110108. PubMed ID: 37394110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mifepristone use for early pregnancy loss: A qualitative study of barriers and facilitators among OB/GYNS in Massachusetts, USA.
    Neill S; Mokashi M; Goldberg A; Fortin J; Janiak E
    Perspect Sex Reprod Health; 2023 Sep; 55(3):210-217. PubMed ID: 37394759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obstetrician-gynecologists' knowledge of and attitudes toward medical abortion in Guatemala.
    Kestler E
    Int J Gynaecol Obstet; 2012 Feb; 116(2):120-3. PubMed ID: 22093500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are US health professionals likely to prescribe mifepristone or methotrexate?
    Koenig JD; Tapias MP; Hoff T; Stewart FH
    J Am Med Womens Assoc (1972); 2000; 55(3 Suppl):155-60. PubMed ID: 10846327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Slow implementation of mifepristone medical termination of pregnancy in Quebec, Canada: a qualitative investigation.
    Guilbert E; Wagner MS; Munro S; Wilcox ES; Dunn S; Soon JA; Devane C; Norman WV
    Eur J Contracept Reprod Health Care; 2020 Jun; 25(3):190-198. PubMed ID: 32312130
    [No Abstract]   [Full Text] [Related]  

  • 7. Exploring Canadian women's knowledge of and interest in mifepristone: results from a national qualitative study with abortion patients.
    Vogel KI; LaRoche KJ; El-Haddad J; Chaumont A; Foster AM
    Contraception; 2016 Aug; 94(2):137-42. PubMed ID: 27125893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical termination of pregnancy in general practice in Australia: a descriptive-interpretive qualitative study.
    Dawson AJ; Nicolls R; Bateson D; Doab A; Estoesta J; Brassil A; Sullivan EA
    Reprod Health; 2017 Mar; 14(1):39. PubMed ID: 28288649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mifepristone Use Among Obstetrician-Gynecologists in Massachusetts: Prevalence and Predictors of Use.
    Newton-Hoe E; Lee A; Fortin J; Goldberg AB; Janiak E; Neill S
    Womens Health Issues; 2024; 34(2):135-141. PubMed ID: 38129219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. US Obstetrician-Gynecologists' Perceived Impacts of Post-Dobbs v Jackson State Abortion Bans.
    Sabbath EL; McKetchnie SM; Arora KS; Buchbinder M
    JAMA Netw Open; 2024 Jan; 7(1):e2352109. PubMed ID: 38231510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers and Facilitators to the Implementation of First Trimester Medical Abortion With Mifepristone in the Province of Québec: A Qualitative Investigation.
    Wagner MS; Munro S; Wilcox ES; Devane C; Norman WV; Dunn S; Soon JA; Guilbert É
    J Obstet Gynaecol Can; 2020 May; 42(5):576-582. PubMed ID: 31924442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "We've got rights and yet we don't have access": Exploring patient experiences accessing medication abortion in Australia.
    LaRoche KJ; Wynn LL; Foster AM
    Contraception; 2020 Apr; 101(4):256-260. PubMed ID: 31927029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers to abortion provision in primary care in New England, 2019-2020: A qualitative study.
    Lee CM; Johns SL; Stulberg DB; Allen RH; Janiak E
    Contraception; 2023 Jan; 117():39-44. PubMed ID: 35970423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early pregnancy termination with mifepristone and misoprostol in Norway.
    Bjørge L; Johnsen SL; Midbøe G; Augestad G; Økland I; Helland H; Stray-Pedersen S; Iversen OE
    Acta Obstet Gynecol Scand; 2001 Nov; 80(11):1056-61. PubMed ID: 11703208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early medical abortion using low-dose mifepristone followed by buccal misoprostol: a large Australian observational study.
    Goldstone P; Michelson J; Williamson E
    Med J Aust; 2012 Sep; 197(5):282-6. PubMed ID: 22938126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of mifepristone and misoprostol for the termination of pregnancy.
    ;
    Int J Gynaecol Obstet; 2011 Oct; 115(1):1-4. PubMed ID: 21872858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Has mifepristone medical abortion expanded abortion access in New Mexico? A survey of OB-GYN and Family Medicine physicians.
    Espey E; Leeman L; Ogburn T; Skipper B; Eyman C; North M
    Contraception; 2011 Aug; 84(2):178-83. PubMed ID: 21757060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions.
    Newhall EP; Winikoff B
    Am J Obstet Gynecol; 2000 Aug; 183(2 Suppl):S44-53. PubMed ID: 10944369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Early Pregnancy Loss Management Between States With Restrictive and Supportive Abortion Policies.
    Tal E; Paul R; Dorsey M; Madden T
    Womens Health Issues; 2023; 33(2):126-132. PubMed ID: 36379879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between abortion restrictions and patient-centered care for early pregnancy loss at US obstetrics-gynecology residency programs.
    Phillips AM; Rachad S; Flink-Bochacki R
    Am J Obstet Gynecol; 2023 Jul; 229(1):41.e1-41.e10. PubMed ID: 37003363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.